Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842415 | 0.98 | EPHX1 (0.49) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| SCHEMBL29171649 | 0.91 | MGAM (0.39) | EPHX1SMN1; SMN2NAAAASAH1 | |
| SCHEMBL27623915 | 0.88 | SMN1; SMN2 (0.44) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| SCHEMBL11880421 | 0.87 | EPHX1 (0.44) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| Hydrochloric Acid SCHEMBL11876947 | 0.85 | EPHX1 (0.43) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| SCHEMBL30997666 | 0.84 | EPHX1 (0.66) | EPHX1SMN1; SMN2NAAAASAH1 | |
| SCHEMBL25022401 | 0.83 | SMN1; SMN2 (0.46) | EPHX1SMN1; SMN2NAAAHPGDLMNA | |
| SCHEMBL6019680 | 0.83 | SMN1; SMN2 (0.46) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| SCHEMBL2265099 | 0.83 | SMN1; SMN2 (0.46) | EPHX1SMN1; SMN2NAAAHPGDASAH1 | |
| SCHEMBL8392600 | 0.83 | SMN1; SMN2 (0.43) | EPHX1SMN1; SMN2NAAAHPGDASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| EP-1994027-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | EPHX1 1858/4885SMN1; SMN2 4089/4885NAAA 69/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | EPHX1 1652/4885SMN1; SMN2 3897/4885NAAA 50/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | EPHX1 1770/4885SMN1; SMN2 3632/4885NAAA 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.